All In Biotech

Drug Trial Radar · NCT06105151

Study of the Safety, Tolerability, Pharmacokinetics and Food Effects of VV119 Capsules in Chinese Healthy Volunteers

A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Food Effects of a Single Oral VV119 Capsule in Healthy Chinese Volunteers

Last checked: Nov 19, 2026Latest source record: Aug 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

82

Planned (sponsor's estimate)

Start

Oct 27, 2023

Primary completion

Oct 2026

Study completion Oct 2026

Sponsor

Lead sponsor
Vigonvita Life SciencesIndustry
Sponsor type
Industry
First posted
Oct 27, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study will consist of 2 parts: Part Ⅰ - Single Ascending Dose (SAD) study, Part Ⅱ - Food Effect (FE) study

Conditions

  • Schizophrenia

Interventions

  • VV119(SAD)Drug

    VV119 0.2 mg Group: 2 subjects will receive VV119 0.2 mg, orally; VV119 0.5 mg Group: 6 subjects will receive VV119 0.5 mg, orally; VV119 1 mg Group: 6 subjects will receive VV119 1 mg, orally; VV119 2 mg Group: 6 subjects will receive VV119 2 mg, orally; VV119 3 mg Group:6 subjects will receive VV119 3 mg, orally; VV119 4.5 mg Group:6 subjects will receive VV119 4.5 mg, orally; VV119 6 mg Group:6 subjects will receive VV119 6 mg, orally; VV119 8 mg Group:6 subjects will receive VV119 8 mg, orally; VV119 10 mg Group:6 subjects will receive VV119 10 mg, orally;

  • VV119 Placebo(SAD)Drug

    VV119 0.5 mg Group: 2 subjects will receive VV119 Placebo 0.5 mg, orally; VV119 1 mg Group: 2 subjects will receive VV119 Placebo 1 mg, orally; VV119 2 mg Group: 2 subjects will receive VV119 Placebo 2 mg, orally; VV119 3 mg Group:2 subjects will receive VV119 Placebo 3 mg, orally; VV119 4.5 mg Group:2 subjects will receive VV119 Placebo 4.5 mg, orally; VV119 6 mg Group:2 subjects will receive VV119 Placebo 6 mg, orally; VV119 8 mg Group:2 subjects will receive VV119 Placebo 8 mg, orally; VV119 10 mg Group:2 subjects will receive VV119 Placebo 10 mg, orally;

  • VV119(FE)Drug

    A:2 mg VV119, following an overnight fast of at least 10 hours for Period 1; 2mg VV119, administered 30 minutes after the start of a high-fat meal for Period 2; B: 2mg VV119, administered 30 minutes after the start of a high-fat meal for Period 1;2mg VV119, following an overnight fast of at least 10 hours for Period 2;

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment-Emergent Adverse EventsTime frame: 23 days after treatment in part Ⅰ;
  2. Incidence of Treatment-Emergent Adverse EventsTime frame: 56 days after treatment in part Ⅱ;
  3. CmaxTime frame: 360 hours after dosing in part Ⅰ;
  4. CmaxTime frame: 480 hours after dosing in part Ⅱ;
  5. area under the plasma concentration time curve from time zero to the last(AUC0-t)Time frame: 360 hours after dosing in part Ⅰ;
  6. area under the plasma concentration time curve from time zero to the last(AUC0-t)Time frame: 480 hours after dosing in part Ⅱ;
  7. AUC0-∞Time frame: 360 hours after dosing in part Ⅰ;
  8. AUC0-∞Time frame: 480 hours after dosing in part Ⅱ;
  9. TmaxTime frame: 360 hours after dosing in part Ⅰ;
  10. TmaxTime frame: 480 hours after dosing in part Ⅱ;
  11. t1/2Time frame: 360 hours after dosing in part Ⅰ;
  12. t1/2Time frame: 480 hours after dosing in part Ⅱ;
  13. Apparent Clearance Rate(CL/F)Time frame: 360 hours after dosing in part Ⅰ;
  14. Apparent Clearance Rate(CL/F)Time frame: 480 hours after dosing in part Ⅱ;
  15. Vd/FTime frame: 360 hours after dosing in part Ⅰ;
  16. Vd/FTime frame: 480 hours after dosing in part Ⅱ;
  17. KeTime frame: 360 hours after dosing in part Ⅰ;
  18. KeTime frame: 480 hours after dosing in part Ⅱ;
  19. mean Resident Time from time zero to the last(MRT0-t)Time frame: 360 hours after dosing in part Ⅰ;
  20. mean Resident Time from time zero to the last(MRT0-t)Time frame: 480 hours after dosing in part Ⅱ;
  21. mean Resident Time from time zero to infinity(MRT0-∞)Time frame: 360 hours after dosing in part Ⅰ;
  22. mean Resident Time from time zero to infinity(MRT0-∞)Time frame: 480 hours after dosing in part Ⅱ;
  23. AUC_%ExtraTime frame: 360 hours after dosing in part Ⅰ;
  24. AUC_%ExtraTime frame: 480 hours after dosing in part Ⅱ;
  25. BPTime frame: 360 hours after dosing in part Ⅰ;
  26. BPTime frame: 480 hours after dosing in part Ⅱ;

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Anding Hospital of Capital Medical University

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.